


AMENDMENTS TO THE CLAIMS:

The following listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-10 (canceled)

Claim 11 (previously presented): A suspension concentrate consisting of

- (a) between 10 and 40% by weight, based on the suspension concentrate, of at least one active compound that is solid at room temperature selected from the group consisting of azaconazole, bitertanol, bromuconazole, cyproconazole, diclobutrazole, difenoconazole, diniconazole, epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, imibenconazole, ipconazole, myclobutanil, paclebutrazol, penconazole, propiconazole, prothioconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triticonazole, dimoxystrobin, fluoxastrobin, kresoxim-methyl, metaminostrobin, picoxystrobin, pyraclostrobin, and trifloxystrobin,
- (b) between 5 and 20% by weight, based on the suspension concentrate, of at least one penetration enhancer selected from the group consisting of alkanolethoxylates of formula (I)



wherein

- m represents numbers from 9 to 13, and
- n represents numbers from 8 to 12,
- (c) between 3 and 8% by weight, based on the suspension concentrate, of at least one dispersant mixture selected from the group consisting of
 - (i) a polymer of methyl 2-methyl-2-propenoate and α -(2-methyl-1-oxo-2-propenyl)- ω -methoxypoly(oxy-1,2-ethanediyl) (CAS No. 111 740-36-4) and a tristyrilphenolethoxylate having an average of 50 to 60 oxyethylene units,

- (ii) a polymer of methyl 2-methyl-2-propenoate and α -(2-methyl-1-oxo-2-propenyl)- ω -methoxypoly(oxy-1,2-ethanediyl) (CAS No. 111 740-36-4) and a propylene oxide/ethylene oxide block copolymer having a molecular weight between 8000 and 10,000 and an ethylene oxide proportion of between 40 and 60% by weight, and
- (iii) a tristyrylphenoethoxylate having an average of 50 to 60 oxyethylene units and a propylene oxide/ethylene oxide block copolymer having a molecular weight between 8000 and 10,000 and an ethylene oxide proportion of between 40 and 60% by weight,
- (d) between 40 and 65% by weight, based on the suspension concentrate, of water, and
- (e) between 0 and 15% by weight, based on the suspension concentrate, of one or more additives.

Claims 12-13 (canceled)

Claim 14 (previously presented): A suspension concentrate according to Claim 11 wherein component (a) is tebuconazole.

Claim 15 (previously presented): A suspension concentrate according to Claim 11 wherein component (a) comprises tebuconazole and trifloxystrobin.

Claim 16 (previously presented): A suspension concentrate according to Claim 11 wherein component (a) comprises prothioconazole and fluoxastrobin.

Claim 17 (previously presented): A suspension concentrate according to Claim 11 wherein component (a) is trifloxystrobin.

Claims 18-21 (canceled)

Claim 22 (previously presented): A suspension concentrate according to Claim 11 wherein m represents 11 and n represents 10.

Claims 23-24 (canceled)